Hull v. Secretary of Health and Human Services

United States Court of Federal Claims·Decided February 4, 2025·No. 24-0847V·Unpublished

Opinion

In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS No. 24-847V UNPUBLISHED

MARY ANNALEE HULL, Chief Special Master Corcoran Petitioner, v. Filed: January 10, 2025 SECRETARY OF HEALTH AND HUMAN SERVICES,

Respondent.

Robert M. Hatch, Bronster Fujichaku Robbins, Honolulu, HI, for Petitioner. Julia M. Collison, U.S. Department of Justice, Washington, DC, for Respondent.

DECISION1

On May 31, 2024, Mary Hull filed a petition for compensation under the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa—10 through 342 (the “Vaccine Act”). Petitioner alleges that she suffered various injuries from two human papillomavirus (“HPV”) vaccinations she received in April 2016 (no specific dates provided).3 ECF No. 1 at 2.

Because the petition was untimely filed, and Petitioner has failed to establish a basis for equitable tolling, this case is DISMISSED.

1 Because this Decision contains a reasoned explanation for the action taken in this case, it must be made publicly accessible and will be posted on the United States Court of Federal Claims' website, and/or at https://www.govinfo.gov/app/collection/uscourts/national/cofc, in accordance with the E-Government Act of 2002. 44 U.S.C. § 3501 note (2018) (Federal Management and Promotion of Electronic Government Services). This means the Decision will be available to anyone with access to the internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to redact medical or other information, the disclosure of which would constitute an unwarranted invasion of privacy. If, upon review, I agree that the identified material fits within this definition, I will redact such material from public access. 2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 300aa (2012). 3 A footnote states that Petitioner received her first HPV vaccine on May 28, 2008, but this statement appears erroneous because, in addition to contradicting the body of the petition, Petitioner would have been six years old at that time. ECF No. 1 at 1 n.1. The earliest the CDC recommends giving children HPV vaccines is nine years old (https://www.cdc.gov/hpv/parents/vaccine-for-hpv.html). Relevant Factual Background

After the April 2016 vaccinations, Petitioner stated that unspecified injuries “progressed in the subsequent years” and she became aware in June 2020 that the HPV vaccine could cause adverse effects. ECF No. 1 ¶¶ 5, 6. Petitioner stated she was later diagnosed with postural orthostatic tachycardia syndrome (POTS). Id. ¶ 8. Petitioner has not filed any medical records to establish these facts.

Petitioner alleged the preceding medical history in the petition and repeated the history in her response to the order to show cause. Facially, Petitioner’s claim herein was filed over eight years after the HPV vaccinations, which were administered in 2016, and over eight years from the time she began manifesting symptoms in 2016. But Petitioner maintains her delay is excusable. Petitioner has only stated, but not attested in an affidavit, that at the time these vaccinations occurred, no Vaccine Information Statement (VIS) was provided, and no information was relayed about the Vaccine Program. Petitioner again only stated, but did not attest, she became aware that the HPV vaccine could have potential adverse effect shortly before filing her vaccine claim in June 2020. As these vaccinations would have occurred when Petitioner was thirteen or fourteen years old, Petitioner similarly did not submit an affidavit from either of her parents, one at least who presumably would have attended the vaccination appointments, about whether any counseling or information was provided about the HPV vaccine or the Vaccine Program.

Relevant Procedural History

Given that the timeliness of the claim was legitimately called into question merely by the face of the actual Petition, while the case was still in the initial “pre-assignment review,”4 I ordered Petitioner to show cause why the claim had not been filed outside the Act’s 36-month statute of limitations. Sec. 16(a)(2); ECF No. 6.

On August 9, 2024, Petitioner filed a response. ECF No. 9. Petitioner did not dispute that her symptoms progressed from 2016 until 2020, or that her petition was filed in 2024 (and not sooner than the statute of limitations deadline), but instead argued that the limitations period should be equitably tolled. Petitioner asserted that she had diligently pursued her rights once she became aware of her legal rights. Petitioner also made allegations not relevant to a Vaccine Act claim, about the perfidious conduct of the vaccine manufacturer in fraudulently concealing the HPV vaccine’s harmful character from the public. ECF No. 9 at 17. Relatedly, Petitioner argued that the failure of a healthcare professional to provide her with a VIS at the time of vaccination can be attributed to the

4 Pre-Assignment Review, or PAR, is a process utilized by the Office of Special Masters to assess whether a claim’s primary evidentiary documentation has been filed. See notice at http://www.uscfc.uscourts.gov/vaccine-programoffice-special-masters.

2 Department of Health and Human Services’ failure to systematically ensure that VIS are explained and provided to all vaccine recipients. Id. at 3.

Respondent submitted a brief of his own, arguing for dismissal due to untimeliness.5 ECF No. 7. Respondent maintained that Petitioner in fact had not diligently pursued her rights before filing a vaccine claim in 2024. Respondent also disputed the veracity of contentions about the manufacturer’s conduct, and whether it could in any event constitute an extraordinary circumstance that would serve as a basis for tolling of the statute.

Legal Standards

The Vaccine Act's statute of limitations is thirty-six months. Sec. 16(a)(2). The statute begins to run from the manifestation of the first objectively cognizable symptom, whether or not that symptom is sufficient for diagnosis (or even recognized by a claimant as significant). Id.; Carson v. Sec'y of Health & Hum. Servs., 727 F.3d 1365, 1369 (Fed. Cir. 2013).

The Federal Circuit has held that the doctrine of equitable tolling can apply to Vaccine Act’s statute of limitations. See Cloer v. Sec'y of Health & Hum. Servs., 654 F.3d 1322, 1340-41 (Fed. Cir. 2011). However, in keeping with applicable U.S. Supreme Court precedent, equitable tolling of a limitations period is to be permitted “sparingly.” Irwin v. Dep't of Veterans Affairs, 498 U.S. 89, 96, (1990). The appropriateness of equitable tolling is ultimately to be determined on a case-by-case basis, without rigid application of any relevant overarching guidelines. Holland v. Florida, 560 U.S. 631, 649–50 (2010); accord Arctic Slope Native Ass'n v. Sebelius, 699 F.3d 1289, 1295 (Fed. Cir. 2012).

Free access — add to your briefcase to read the full text and ask questions with AI

Hull v. Secretary of Health and Human Services, (uscfc 2025).

Hull v. Secretary of Health and Human Services (Hull v. Secretary of Health and Human Services) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Irwin v. Department of Veterans Affairs
498 U.S. 89 (Supreme Court, 1991)
Cloer v. Secretary of Health and Human Services
654 F.3d 1322 (Federal Circuit, 2011)
Arctic Slope Native Association, Ltd. v. Sebelius
699 F.3d 1289 (Federal Circuit, 2012)
Carson v. Secretary of Health & Human Services
727 F.3d 1365 (Federal Circuit, 2013)
Menominee Indian Tribe of Wis. v. United States
577 U.S. 250 (Supreme Court, 2016)